Santral Sinir Sisteminin Fungal Enfeksiyonları

Katarzyna Góralska K, Blaszkowska J, Dzikowiec M Neuroinfections caused by fungi. Infection 2018; 46:443–459.

Sharma RR. Fungal infections of the nervous system: current perspective and controversies in management. Int J Surg 2010;8:591–601.

Köhler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. Cold Spring Herb Perspect Med 2015;5:a019273.

Murthy JMK, Sundaram C. Fungal infections of the central nervous system. In. Biller J, Ferro JM, (eds). Handbook of clinical neurology. Elsevier, New York, 2014; 1383–401.

Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi 2017;3:57.

McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold Infections of the central nervous system. N Engl J Med 2014;371:150–60.

Microbiology and epidemiology of Cryptococcus neoformans infection. Cox GM, Perfect JR . Erişim: www.uptodate.com. Apr 28, 2021.

Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690.

Diamond RD, May JE, Kane MA, et al. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol 1974; 112:2260.

Kwon-Chung KJ, Rhodes JC. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans. Infect Immun 1986; 51:218.

Wong B, Perfect JR, Beggs S, Wright KA. Production of the hexitol D-mannitol by Cryptococcus neoformans in vitro and in rabbits with experimental meningitis. Infect Immun 1990; 58:1664.

Cox, GM, Perfect, JR. Cryptococcus neoformans var neoformans and gattii and Trichosporon species. In: Topley and Wilson's Microbiology and Microbial Infections, 9th ed, Ajello, Edward (Ed), Arnold Press, London 1997.

Qu J, Zhou T, Zhong C, et al. Comparison of clinical features and prognostic factors in HIV-negative adults with cryptococcal meningitis and tuberculous meningitis: a retrospective study. BMC Infect Dis 2017; 17:51.

Shaunak S, Schell WA, Perfect JR. Cryptococcal meningitis with normal cerebrospinal fluid. J Infect Dis 1989; 160:912.

Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756.

Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993; 342:1119.

McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985; 21:681.

Westerink MA, Amsterdam D, Petell RJ, et al. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am J Med 1987; 83:155.

Rhein J, Bahr NC, Hemmert AC, et al. Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda. Diagn Microbiol Infect Dis 2016; 84:268.

O'Halloran JA, Franklin A, Lainhart W, et al. Pitfalls Associated With the Use of Molecular Diagnostic Panels in the Diagnosis of Cryptococcal Meningitis. Open Forum Infect Dis 2017; 4:ofx242.

Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326:83.

Charlier C, Dromer F, Lévêque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One 2008; 3:e1950.

American Academy of Pediatrics. Cryptococcosis. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021 Report of the Committee on Infectious Diseases. Itasca, IL: American Academy of Pediatrics: 2021; 285–288.

Kantarcioglu AS, Guarro J, De Hoog S, et al. An updated comprehensive systematic review of Cladophialophora bantiana and analysis of epidemiology, clinical characteristics, and outcome of cerebral cases. Med Mycol 2017; 55:579.

al-Hedaithy SS, Jamjoom ZA, Saeed ES. Cerebral phaeohyphomycosis caused by Fonsecaea pedrosoi in Saudi Arabia. APMIS 1988; 3:94.].

Fletcher H, Williams NP, Nicholson A, et al. Systemic phaeohyphomycosis in pregnancy and the puerperium. West Indian Med J 2000; 49:79.

del Palacio-Hernanz A, Moore MK, Campbell CK, et al. Infection of the central nervous system by Rhinocladiella atrovirens in a patient with acquired immunodeficiency syndrome. J Med Vet Mycol 1989; 27:127.

Delfino D, De Hoog S, Polonelli L, et al. Survival of a neglected case of brain abscess caused by Cladophialophora bantiana. Med Mycol 2006; 44:651.

Al-Abdely HM, Najvar L, Bocanegra R, et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother 2000; 44:1159.

Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150:101.

Rivard RG, McCall S, Griffith ME, et al. Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection. Med Mycol 2007; 45:685.

Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20:121.

Blyth CC, Chen SC, Slavin MA, et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics 2009; 123:1360.

Pana ZD, Kotzadamis D, Roilides E. Invasive Candidiasis in Pediatric Intensive Care Unit: More Challenges. Pediatr Infect Dis J 2018; 37:1309.

McCullers JA, Vargas S, Flynn PM, Razzouk BI, Shenep JL. Candidal meningitis in children with cancer. Clin Infect Dis. 2000; 31:451–457.

Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med 2015; 373:1445.

Hegde SV, Dillman JR, Lopez MJ, Strouse PJ. Imaging of multifocal liver lesions in children and adolescents. Cancer Imaging 2013; 12:516.

Yen TY, Huang LM, Lee PI, et al. Clinical characteristics of hepatosplenic fungal infection in pediatric patients. J Microbiol Immunol Infect 2011; 44:296.

Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018; 67:e1.

Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.

Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640.

Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 2007; 119:772.

Candida infections of the central nervous system. Kauffman CA. Erişim: uptodate.com

Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004; 23:635.

Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110.

Saubolle MA, McKellar PP, Sussland D. Epidemiologic, clinical, and diagnostic aspects of coccidioidomycosis. J Clin Microbiol 2007; 45:26.

Umeyama T, Sano A, Kamei K, et al. Novel approach to designing primers for identification and distinction of the human pathogenic fungi Coccidioides immitis and Coccidioides posadasii by PCR amplification. J Clin Microbiol 2006; 44:1859.

Johnson RH, Einstein HE. Coccidioidal Meningitis. Clin Infect Dis. 2006; 42:103–107.

Kassis C, Zaidi S, Kuberski T, et al. Role of Coccidioides Antigen Testing in the Cerebrospinal Fluid for the Diagnosis of Coccidioidal Meningitis. Clin Infect Dis 2015; 61:1521.

Arsura EL, Johnson R, Penrose J, et al. Neuroimaging as a guide to predict outcomes for patients with coccidioidal meningitis. Clin Infect Dis. 2005; 40:624–627.

Galgiani JN, Ampel NM, Blair JE, et al. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clin Infect Dis 2016; 63:e112.

Proia LA, Tenorio AR. Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother. 2004; 48:2341.

Shamim MS, Enam SA, Ali R, Anwar S. Craniocerebral aspergillosis: a review of advances in diagnosis and management. J Pak Med Assoc. 2010;60:573–9.

Mohammadi H, Sadeghi S, Zandi S. Central nervous system aspergilloma in an immunocompetent patient: a case report. Iran J Public Health. 2015;44:869–72.

Salehpour F, Aghazade J, Lotfinia I, Shokouhi G, Shakeri M, Shimia M, et al. Brain abscess due to Aspergillus in an immunocompetent patient. EC Neurology. 2016;3.3:388–91.

Sivak-Callcott JA, Livesley N, Nugent RA, et al. Localised invasive sino-orbital aspergillosis: characteristic features. Br J Ophthalmol 2004; 88:681.

Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a General Hospital and review of 123 cases from the literature. Medicine. 2012;91:328–36. https ://doi.org/10.1097/MD.0b013 e3182 74cd7 7.

Vergara GE, Roura N, Del Castillo M, Mora A, Alcorta SC, Mormandi R, Cervio A, Salvat J. Cervical aspergillosis with dissemination to the central nervous system: Case reports and review of the literature. Surg Neurol Int. 2015;6:S524-9. https :// doi.org/10.4103/2152-7806.16720 3.

Panda PK, Mavidi SK, Wig N, Garg A, Nalwa A, Sharma MC. Intracranial aspergillosis in an immunocompetent young woman. Mycopathologia. 2017;182:527–538. https ://doi.org/10.1007/ s1104 6-016-0106-4.

Rossouw I, Goedhals D, van der Merwe J, Stallenberg V, Govender N. A rare, fatal case of invasive spinal aspergillosis in an antiretroviral-naïve, HIV-infected man with pre-existing lung colonization. J Med Microbiol. 2011;60:1534–8. https ://doi. org/10.1099/jmm.0.03114 6-0.

Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253.

Nadkarni T, Goel A. Aspergilloma of the brain: an overview. J Postgrad Med. 2005;51:S37-41.

Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.

Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 2021; 397:499.

Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016; 387:760.

Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162:81.

Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943.

Kauffman CA, Malani AN. Zygomycosis: an emerging fungal infection with new options for management. Curr Infect Dis Rep 2007; 9:435.

Abdollahi A, Shokohi T, Amirrajab N, Poormosa R, Kasiri AM, Motahari SJ, et al. Clinical features, diagnosis, and outcomes of rhino-orbito-cerebral mucormycosis—a retrospective analysis. Curr Med Mycol. 2016;2:15–23. https ://doi.org/10.18869 /acadp ub.cmm.2.4.15.

Siroos B, Sharify Bahram ZS, Ghaemi O, Zia Ziabari SM, Hedayat Yaghoobi M. A case of progressive rhino-orbital mucormycosis involving the brain via direct extention, retrograde perineural spreading and middle cerebral artery vasculopathy. Arch Clin Infect Dis. 2014;9:e17580. https ://doi.org/10.5812/archcid.17580 .

Gen R, Horasan ES, Vaytsoglu Y, Arpaci RB, Esoz G, Ozcan C. Rhino-orbito-cerebral mucormycosis in patients with diabetic ketoacidosis. J Craniofacial Surg. 2013;24:e144-7. https ://doi. org/10.1097/SCS.0b013 e3182 7c7eb 8.

Sundaram C, Mahadevan A, Laxmi V, Yasha TC, Santosh V, Murthy K, et al. Cerebral zygomycosis Mycoses. 2005;48:396– 407. https ://doi.org/10.1111/j.1439-0507.2005.01167 .x.

Vironneau P, Kania R, Morizot G, Elie C, Garcia-Hermoso D, Herman P, et al. Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival. Clin Microbiol Inf. 2014;20:O336-9. https ://doi.org/10.1111/1469-0691.12408 .

Bozorgi V, Talebitaher M, Shalbaf N, Radmanesh N, Nasri F, Ansari-Ramandi MM. Epidemiological aspects and clinical outcome of patients with rhinocerebral zygomycosis: a survey in a referral hospital in Iran. Pan African Med J. 2016;24:232. https ://doi.org/10.11604 /pamj.2016.24.232.9688.

Ling H, Yuan Z, Shen J, et al. Accuracy of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinical pathogenic fungi: a meta-analysis. J Clin Microbiol 2014; 52:2573.

Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am 2016; 30:143.

Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19:e405.

Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.

Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634.

Chu JH, Feudtner C, Heydon K, et al. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 2006; 42:822.

Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007; 20:115.

Medoff G, Kobayashi GS, Painter A, Travis S. Morphogenesis and pathogenicity of Histoplasma capsulatum. Infect Immun. 1987; 55:1355–1358.

Azar MM, Loyd JL, Relich RF, et al. Current Concepts in the Epidemiology, Diagnosis, and Management of Histoplasmosis Syndromes. Semin Respir Crit Care Med 2020; 41:13.

Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011; 53:448.

Wheat LJ, Musial CE, Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis. 2005; 40:844–852.

Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807.